AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29533864
Drug: Intramuscular oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular oxytocin administration immediately following placental delivery (10 IU)
Trial: 26751193
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus hesperidin (500 g hesperidin with 500 mg calcium)
Trial: 15831773
Drug: Fenofibrate (201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (201 mg/d)
Trial: 17394563
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg twice daily)
Trial: 15831773
Drug: Combined fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined fenofibrate (201 mg/d) plus rosiglitazone (4 mg twice daily)
Trial: 8998248
Drug: Amlodipine (AML)
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine (AML) 5 to 10 mg once daily
Trial: 8998248
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 12.5 to 25 mg once daily
Trial: 8998248
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (HCTZ + AML) after 8 weeks of monotherapy
Trial: 363217
Drug: Preoperative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative and postoperative metronidazole medication
Trial: 363217
Drug: Preoperative mechanical
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative mechanical bowel preparation and oral neomycin
Trial: 29600588
Drug: 6-month programmed
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month programmed sports therapy (PST)
Trial: 23650950
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 600 mg HR, Thioctacid, three doses
Trial: 9445301
Drug: Inhaled recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled recombinant human IL-5
Trial: 7822813
Drug: IL-1 receptor
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-1 receptor antagonist (IL-1ra) infusion (133 mg/h)
Trial: 7822813
Drug: IL-1ra infusion
RxNorm normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IL-1ra infusion with endotoxin
Trial: 7822813
Drug: Control study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control study day (no treatment)
Trial: 2214478
Drug: Intravesical BCG
RxNorm normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical BCG (80 mg Tokyo strain) administered at one week intervals for 6 weeks, two week intervals for 12 weeks, and one month intervals for 20 months.
Trial: 2214478
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no further treatment after TUR).
Trial: 28685911
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention plus herbal medicine (two tablets: Tablet 1 with Cinnamomum verum, Glycyrrhiza glabra, Hypericum perforatum, Paeonia lactiflora; Tablet 2 with Tribulus terrestris)
Trial: 28685911
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention plus herbal medicine
Trial: 21802567
Drug: Daily dark
RxNorm normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 70 mg in 1 mL TOPICAL LOTION [La Roche Posay Laboratoire Dermatologique Pigmentclar Daily Dark Spot Correcting Moisturizer Broad Spectrum SPF 30 Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dark chocolate snack
Trial: 19015329
Drug: Saquinavir/ritonavir (1,000/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir/ritonavir (1,000/100 mg twice daily) alone for 14 days
Trial: 19015329
Drug: Ketoconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (200 mg once daily)
Trial: 19015329
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of saquinavir/ritonavir and ketoconazole
Trial: 19015329
Drug: Saquinavir/ritonavir (1,000/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir/ritonavir (1,000/100 mg twice daily) with ketoconazole (200 mg once daily)
Trial: 14722170
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine infusion of 10 micro g h(‐1) kg(‐1)
Trial: 14722170
Drug: 3-hourly intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-hourly intravenous morphine boluses of 30 micro g kg(‐1)
Trial: 14722170
Drug: Morphine hydrochloride
RxNorm normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine hydrochloride infusion of 5 micro g h(‐1) kg(‐1) at birth (term neonates)
Trial: 14722170
Drug: Morphine hydrochloride
RxNorm normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine hydrochloride infusion of 8.5 micro g h(‐1) kg(‐1) at 1 month
Trial: 14722170
Drug: Morphine hydrochloride
RxNorm normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine hydrochloride infusion of 13.5 micro g h(‐1) kg(‐1) at 3 months
Trial: 14722170
Drug: Morphine hydrochloride
RxNorm normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine hydrochloride infusion of 18 micro g h(‐1) kg(‐1) at 1 year
Trial: 14722170
Drug: Morphine hydrochloride
RxNorm normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine hydrochloride infusion of 16 micro g h(‐1) kg(‐1) for 1- to 3-yr-old children
Trial: 11885871
Drug: Nifedipine 10-20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10-20 mg twice daily
Trial: 8167511
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g of alcohol in the form of beer, wine, or spirits with dinner
Trial: 3280148
Drug: Controlled ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ventilation (IPPV) with halothane 0.5‐1%, N2O 66%, and pancuronium 0.05 mg.kg‐1 (n = 60)
Trial: 26960416
Drug: Matured hop
RxNorm normalized name: HOPS
DrugBank: Hops (DB10687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matured hop extract (MHE) containing 35 mg MHBA, ingested daily for 12 weeks.
Trial: 26960416
Drug: Placebo beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo beverage without MHE, ingested daily for 12 weeks.
Trial: 18984759
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (25 patients)
Trial: 11170151
Drug: Saw palmetto
RxNorm normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saw palmetto extract (320 mg o.d.)
Trial: 9670433
Drug: HBO2 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HBO2 therapy at 2.5 atm abs pressure for 90 min daily for a total of five treatments, starting 1 h after the operation.
Trial: 31051059
Drug: HBO2 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HBO2 therapy
Trial: 9670433
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no HBO2 therapy)
Trial: 2980760
Drug: Medication M
RxNorm normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication M (Monobeltin) - 1,050 mg ASA with enteric coat
Trial: 2980760
Drug: Medication C
RxNorm normalized name: POUCH,MEDICATION CRUSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication C (Colfarit) - 1,000 mg microencapsulated ASA
Trial: 29985380
Drug: Para-articular oxygen/ozone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Para-articular oxygen/ozone therapy at a permanent ozone concentration of 8 gr/l (injection area 15-20 sq.cm)
Trial: 29985380
Drug: Generic drug-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic drug-based treatment alone
Trial: 29985380
Drug: Para-articular oxygen/ozone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Para-articular oxygen/ozone therapy
Trial: 29985380
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with oxygen/ozone therapy
Trial: 27155232
Drug: UVB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVB treatment (4.3-8.7 J/cm²)
Trial: 27155232
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral drops and Woods lamp)
Trial: 23086704
Drug: Mild protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild protocol (FSH 150 IU/day from day 4 followed by GnRH-antagonist from day 8; n=205)
Trial: 20583915
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with autogenous periosteal membranes and autogenous bone chips (aCPRT)
Trial: 18025536
Drug: ARC1779 (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARC1779 (0.05 to 1.0 mg/kg)
Trial: 16128862
Drug: rosuvastatin 40
RxNorm normalized name: rosuvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 40 mg day(-1) for 12 weeks
Trial: 11292279
Drug: Individuals with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individuals with one or two long (l) 5HTTLPR alleles
Trial: 11292279
Drug: Individuals with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individuals with one or two long (l) 5HTTLPR alleles or higher CSF 5HIAA levels
Trial: 8719005
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg gemeprost vaginal pessary administered at 6h intervals
Trial: 25970116
Drug: Intravenous PTX
RxNorm normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PTX 5 mg/kg/hr for 6 hours on 6 successive days
Trial: 23234647
Drug: Mavrilimumab 10
RxNorm normalized name: Mavrilimumab
DrugBank: Mavrilimumab (DB12534)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavrilimumab 10 mg
Trial: 23234647
Drug: Mavrilimumab 50
RxNorm normalized name: Mavrilimumab
DrugBank: Mavrilimumab (DB12534)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavrilimumab 50 mg
Trial: 19829036
Drug: IV midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV midazolam (1 ml)
Trial: 15561813
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 40,000 U weekly (QW)
Trial: 8221741
Drug: Captopril pretreatment
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril pretreatment (6.25 mg orally 15 min before thrombolysis) in Group A
Trial: 8221741
Drug: Captopril late
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril late treatment (administered about 3 days after thrombolysis) in Group B
Trial: 8221741
Drug: Captopril late
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril late treatment in Group B
Trial: 30656782
Drug: Endodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endodontic treatment
Trial: 30656782
Drug: Prophylaxis and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis and topical fluoride (control)
Trial: 18756983
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy (clopidogrel 75 mg plus aspirin 100 mg)
Trial: 18756983
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (low molecular weight heparin for 7 days plus long-term warfarin)
Trial: 16179787
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg rabeprazole for 2 days and 1 hour before the test
Trial: 12540640
Drug: Chelation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chelation therapy with calcium disodium EDTA for 3 months followed by repeated therapy weekly for 24 months (32 patients with high-normal body lead burdens).
Trial: 12540640
Drug: Placebo infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusions for 5 weeks every 6 months (32 control patients).
Trial: 10100068
Drug: Subjects with
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with low renin levels (< 10 mU/l; n = 118)
Trial: 10100068
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving diuretics (n = 39)
Trial: 10100068
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving beta-blockers (n = 54)
Trial: 10100068
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving angiotensin-converting enzyme inhibitors (n = 9)
Trial: 10100068
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving Ca(2+)-antagonists (n = 19)
Trial: 29920980
Drug: Bapineuzumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bapineuzumab (5 mg, 10 mg, 20 mg, 40 mg, 80 mg)
Trial: 25166750
Drug: 3000 IU
RxNorm normalized name: Cholecalciferol 3000 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 IU of oral cholecalciferol daily for 4 months
Trial: 17599630
Drug: alpha-galactosylceramide (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-galactosylceramide (any dose)
Trial: 14701781
Drug: Methadone (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (7.5 mg orally every 12 hours and 5 mg every 4 hours as needed)
Trial: 14701781
Drug: Morphine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (15 mg sustained release every 12 hours and 5 mg every 4 hours as needed)
Trial: 3528988
Drug: Both Methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Methadone and Morphine
Trial: 10396343
Drug: Melarsoprol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melarsoprol treatment
Trial: 7978143
Drug: Intravenous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol infusion while breathing 100% oxygen
Trial: 27824253
Drug: 3.5 ml
RxNorm normalized name: ethanol 3.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 ml of radiolabeled (1 mCi 99mTc-DTPA) universal placebo, hydroxyethyl cellulose gel
Trial: 27824253
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of radiolabeled (1 mCi 99mTc-DTPA) universal placebo, hydroxyethyl cellulose gel
Trial: 25926088
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin (2,500 U)
Trial: 25926088
Drug: High-dose heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose heparin (5,000 U)
Trial: 19218138
Drug: Phosphocreatine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphocreatine treatment (8 weeks)
Trial: 2666363
Drug: Adjuvant CMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant CMF chemotherapy
Trial: 3904436
Drug: Isoxicam at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoxicam at a dosage greater than 200 mg per day
Trial: 3904436
Drug: Isoxicam at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoxicam at 200 mg per day
Trial: 3904436
Drug: Buffered aspirin
RxNorm normalized name: Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buffered aspirin at 3,600 to 4,800 mg per day
Trial: 3904436
Drug: Indomethacin at
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin at 150 mg per day
Trial: 31166081
Drug: Fasudil 60
RxNorm normalized name: fasudil
DrugBank: Fasudil (DB08162)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Fasudil 60 mg
Trial: 31166081
Drug: Fasudil 30
RxNorm normalized name: fasudil
DrugBank: Fasudil (DB08162)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Fasudil 30 mg
Trial: 30307816
Drug: Aqueous solution
RxNorm normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous solution containing betaine, zinc and polyhexamethylene biguanide (polihexanide)
Trial: 30307816
Drug: 3% saline
RxNorm normalized name: dextrose 2.5%-0.3% saline (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% saline solution containing 0.2% sodium hypochlorite
Trial: 30307816
Drug: Irrigation solution
RxNorm normalized name: Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigation solution containing sea salt 1.2% and NaOCl 0.4%
Trial: 24382109
Drug: Culturally Adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally Adapted Cognitive Behaviour Therapy for Psychosis (CaCBTp)
Trial: 24279026
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (group D, control)
Trial: 21262590
Drug: Continuous administration
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous administration of combined oral estroprogestins (CON)
Trial: 21262590
Drug: Cyclic administration
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic administration of combined oral estroprogestins (CYC)
Trial: 12698853
Drug: Doxocycline (DC)
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxocycline (DC) 200 mg/day
Trial: 12698853
Drug: Erythromycin (EM)
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin (EM) 2 g/day
Trial: 12698853
Drug: Ciprofloxacin (CF)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (CF) 1 g/day
Trial: 12698853
Drug: Co-trimoxazole (CT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (CT) 1920 mg/day
Trial: 8365932
Drug: Progressively higher
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressively higher total doses of hepatic irradiation
Trial: 3521717
Drug: Acyclovir tablets
RxNorm normalized name: Acyclovir Tablets
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir tablets (400 mg) administered five times daily
Trial: 3521717
Drug: Acyclovir ophthalmic
RxNorm normalized name: acyclovir Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir ophthalmic ointment administered five times daily
Trial: 18481719
Drug: Auricular point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular point sticking combined with Tongshiji treatment
Trial: 18481719
Drug: Simple Tongshiji
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple Tongshiji treatment (control group)
Trial: 1587377
Drug: Immunotherapy utilizing
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy utilizing the husband's lymphocytes
Trial: 1587377
Drug: Immunosuppressant and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressant and anticoagulant therapy